# Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

> **NCT05247268** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 104 (estimated)

## Conditions studied

- Endometrial Neoplasm Malignant Stage I

## Interventions

- **DRUG:** Megestrol Acetate 160 MG Oral Tablet
- **DRUG:** Medroxyprogesterone Acetate 500 MG
- **DRUG:** Triprorelin Acetate
- **DRUG:** Letrozole 2.5mg

## Key facts

- **NCT ID:** NCT05247268
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-11
- **Primary completion:** 2027-03-10
- **Final completion:** 2027-09-10
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2025-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05247268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05247268, "Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05247268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*